Browse the corpus

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) usually identified by a translocation of the CCND1 gene. The variety of morphologic variants may make this a challenging diagnosis, although most cases are uncomplicated. It typically follows an aggressive clinical course, although an indolent leukemia variant has been described. This activity illustrates the evaluation and treatment for mantle cell lymphoma and reviews the role of the interprofessional team and new management strategies in managing patients with this condition. Objectives: Describe the pathophysiology and staging of mantle cell lymphoma. Describe the typical immunohistochemistry findings associated with mantle cell lymphoma. Outline the different treatment strategies and investigational treatments in the pipeline in mantle cell lymphoma. Identifying complications associated with MCL treatments. Explore healthcare team strategies for improving care coordination, communication, and new concepts and developments to advance mantle cell lymphoma outcomes. Access free multiple choice questions on this topic.

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by an (11,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. It typically follows an aggressive clinical course (aggressive MCL), although an indolent leukemia variant (indolent MCL) has been described.

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200 000 people. MCL comprises around 5% of all non-Hodgkins lymphomas. MCL is more common in men (3 to 1), and the median age at diagnosis ranges from 60 to 70 years old.

MCL is characterized by reciprocal chromosomal translocation t(11;14)(q13:q32), resulting in the juxtapositioning of cyclin D1 locus to immunoglobulin heavy chain gene locus.[1] This leads to constitutive expression of cyclin D1 (CCND1), which plays a significant role in tumor cell proliferation via cell cycle dysregulation, chromosomal instability, and epigenetic regulation. Rare cases without this translocation may have a CCND2 or 3 translocations.[2] Hypothetical models of molecular subtypes have been proposed based on the cell of origin that correlates to clinical phenotypes. Arising from naive B cells that have no or limited iGVH mutations and express SOX 11 are the classical MCL or aggressive MCL. SOX 11 is a neural transcription factor reported to block terminal B cell differentiation.[3]  Arising from antigen-experienced B cells that have undergone IGVH somatic hypermutations and typically SOX 11 negative and genetically stable B cells are the indolent variant of MCL.[4]

Although only a single translocation defines MCL, there are several morphologic variations that one must know. In lymph nodes, there is often diffuse or nodular effacement of the lymph node. MCL may also show expansion of the mantle zones with a monocytoid appearance surrounding reactive germinal centers. Often pink histiocytes may be mixed with lymphoma cells (see image). Pathologic exam with samples from tissue biopsy is essential for the diagnosis of MCL, which typically shows small lymphocytes with cells characterized by notched nuclei in the small cell or blastoid variant type. The cytology of the cells is highly variable as well. In tissue, cells may appear small and mature with irregular nuclei, but in the blastoid variant, they may appear immature with fine chromatin mimicking acute leukemia. The pleomorphic variant shows a marked variation in nuclear size and shape. The proliferation index and mitotic are also highly variable. In blood and bone marrow aspirate smears, lymphoma cells may have discrete vacuoles, which may be a clue in subtle cases.[5]

The disease is typically widespread at diagnosis. The most common manifestations of MCL include extensive lymphadenopathy, fevers, night sweats, weight loss symptoms, splenomegaly-related discomfort, and blood count abnormalities due to bone marrow involvement and symptoms related to extranodal organ involvement.[6] Extranodal involvement, especially of the gastrointestinal tract, spleen, and bone marrow, is fairly common in MCL.[7] MCL has shared features of both indolent (incurable nature) and aggressive (aggressive clinical phenotype).

Excisional biopsy of a lymph node or an involved extranodal site is essential in the diagnosis of MCL. Laboratory exams, including CBC with differential, LDH, and beta-2 microglobulin, bone marrow biopsy, and imaging (CT or FDG-PET/CT) are also recommended as the standard diagnostic workup. Further, the Ki-67 index and mutation status of p53, ATM, and CCND1 are also important in selecting the optimal treatment. A CSF study is also necessary to rule out CNS involvement and guide appropriate management in MCL patients with a high Ki-67 index (greater than 30%), blastoid variant, or neurologic symptoms.[8] Though GI tract involvement is common in MCL, the routine endoscopic evaluation is unnecessary for all cases since it does not affect the management. But GI workup is recommended in the suspected stage I and non-bulky stage II for appropriately staging early-stage MCL. Immunohistochemistry on pathology specimens plays an essential role in differentiating MCL from other NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). MCL is positive for B-cell markers (CD19, CD20, CD22, CD79a).  It is distinguished from other B-cell lymphomas by diffuse positivity for cyclin D1 and SOX11. SOX 11 is usually negative in indolent MCL. Rare cases are negative for cyclin D1 but can still be positive for SOX11. MCL is typically negative for BCL6, CD10, and CD23 (while CLL is CD23 positive). Rare cases of MCL are CD10 positive.[9] Peripheral blood flow cytometry can have CD 200 expression characteristic of MCL. Testing for P53 mutation is recommended to help in the prognostication of MCL. MIPI ( Mantle cell lymphoma international prognostic index) is a scoring system is used to stratify the risk of patients with MCL with pneumonic APLE to remember for readers.[10] Age Performance status LDH Elevated white blood count Using these parameters, scoring calculators are available for free (online) that can help educate patients about their prognosis and expected survival based on these calculations of their survival. However, the MIPI scoring system falls short in predicting prognosis in all MCL patients. Therefore the addition of KI 67, cytogenetics, and TP 53 mutations can help improve the risk stratification of MCL.

Using these parameters, scoring calculators are available for free (online) that can help educate patients about their prognosis and expected survival based on these calculations of their survival. However, the MIPI scoring system falls short in predicting prognosis in all MCL patients. Therefore the addition of KI 67, cytogenetics, and TP 53 mutations can help improve the risk stratification of MCL. High-risk MIPI score patients have median Overall survival (OS ) of 2.8 yrs, while low-risk MIPI had survival longer than 5 years.[11][12] Typically based on symptoms and presentation, patients can be divided into indolent MCL or aggressive MCL. Table Table. Title.

MCL remains a largely incurable disease with a median overall survival (OS) ranging from 1.8 to 9.4 years, depending on whether it is aggressive or indolent MCL. The choice of optimal treatment usually has its basis in the aggressiveness of the disease, performance status, age, and mantle cell international prognostic index (MIPI) score since there is no curative standard treatment established for MCL. Indolent forms of MCL with low MIPI score, hypermutated IGH genes, SOX11 negativity, and non-complex karyotype may be monitored without immediate treatment. As such, watch and wait is appropriate in patients who have 1) Ki-67 = 30%, 2) maximum tumor diameter less than 3 cm, normal serum LDH level, 4) normal beta-2 microglobulin level, 5) no B symptoms, and 6) non-blastoid histology.[13] Table It is rare to find early stage I or non-bulky stage II that can be treated by involved field radiation alone or with nonaggressive regimens used for transplant-ineligible patients. Symptomatic patients with classic MCL (aggressive MCL) that need treatments (Stage II bulky or stage III or stage IV can be classified as stem cell transplant eligible or nontransplant eligible based on performance status and comorbidities. Table Aggressive chemo regimens used: RCHOP alternating with RDHAP; or NORDIC regimen ( Maxi RCHOP alternating with Rituximab and high dose Cytarabine or Hyper-CVAD that includes a CHOP-like regimen alternating with high-dose methotrexate and cytarabine R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone), BR (bendamustine, rituximab), R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin), hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and high dose cytarabine) Patients with relapsed or refractory disease require more aggressive treatment, which is typically a salvage regimen followed by HDC and autologous or allogeneic SCT. Other second-line targeted agents with fewer side effects that are now FDA-approved include Table Inhibit constitutively activated B cell receptor (BCR) signaling through inhibiting BTK downstream from BCR in mantle cell and also  immunomodulatory effects on T cells Acalubritinib and  zanubrutinib bind to cysteine 481 of BTK (more...)

Patients with relapsed or refractory disease require more aggressive treatment, which is typically a salvage regimen followed by HDC and autologous or allogeneic SCT. Other second-line targeted agents with fewer side effects that are now FDA-approved include Table Inhibit constitutively activated B cell receptor (BCR) signaling through inhibiting BTK downstream from BCR in mantle cell and also  immunomodulatory effects on T cells Acalubritinib and  zanubrutinib bind to cysteine 481 of BTK (more...) Ibrutinib, acalabrutinib, zanubrutinib, venetoclax +/- rituximab, bortezomib +/- rituximab, lenalidomide plus rituximab, ibrutinib and lenalidomide + rituximab and chimeric antigen receptor T-cells (CAR-T) received FDA approval and several other agents including BiTE antibodies, antibody-drug conjugates and are under clinical trials. BCR- B cell receptor, BTK - Bruton's tyrosine kinase

The differential diagnosis primarily includes SLL/CLL and DLBCL. Both SLL/CLL and mantle cell lymphoma are CD5-positive, mature B-cell lymphomas and may be difficult to distinguish by flow cytometry alone. When there is positivity for CD200 and CD23, the diagnosis is most likely SLL/CLL. Mantle cell lymphoma is typically negative for CD23; it is positive for FMC7. Confirmation of MCL is typically performed by either FISH for t(11;14) or immunohistochemistry for cyclin D1 and/or SOX11. In tissue, uniform positive immunohistochemical expression of B-cells by Cyclin D1 and SOX 11 supports MCL. Focal positivity for Cyclin D1 may be seen in the proliferation centers of SLL/CLL and should not prompt a diagnosis of MCL.[29] Diffuse large B-cell lymphoma is entertained when large cell proliferation is negative for Cyclin D1 and SOX11. When the architecture of a lymph node is intact and only shows focal involvement by atypical cyclin D1 positive cells, mantle cell neoplasia in situ may be a diagnostic consideration.

Involved site radiation therapy (ISRT) to 24-36 Gy for stages IA and stage II A MCL is recommended with or without combination chemoimmunotherapy. This recommendation is based on retrospective and anecdotal data with PFS at 5 years of 68%.[30] Considering the rarity of finding such early-stage MCL patients and the nonavailability of clinical trial data, ISRT is included in guidelines based on retrospective data.

Chemoimmunotherapies as frontline treatment, and targeted drugs as second-line treatments. Ongoing clinical trials are evaluating combination treatment strategies and new drugs. While it is beyond the scope of this discussion to list out all the ongoing clinical trials, we felt it is important to elucidate the concept underlying these trials as below for the readers. Table Ibrutinib + Venetoclax Combination Regimens MRD: Minimal residual disease; ASO-PCR: allele-specific oligonucleotide PCR; ctDNA: circulating tumor DNA.

Initial staging requires comprehensive scanning, including a contrast CT chest/abdomen/pelvis and/or whole-body PET/CT scan, along with a bone marrow biopsy with aspirate to assess the burden of disease. The staging system that is used for non-Hodgkin's lymphomas is used for the staging of MCL. Table

Although International Prognostic Index (IPI) failed to show prognostic power in MCL, MCL IPI (MIPI) that incorporates age, performance status, normalized LDH level, and white blood cell (WBC) count, was shown to discriminate MCL patients into three risk groups; low, intermediate, and high with a five-year overall survival (OS) of 60%, 35%, and 20%, respectively. Two other prognostic indexes were developed recently to accommodate the prognostic impact of Ki-67 (MIPIb) and simplify calculation (sMIPI), although they require further clinical validation.[31] Further, CDKN2A and TP53 deletions showed inferior OS independent to Ki-67 in patients treated with autologous stem cell transplant (SCT), and TP53 overexpression was shown to correlate with a worse prognosis.[32]  Patients who present with involvement of the peripheral blood and bone marrow (leukemic non-nodal MCL) may follow an indolent course.[33]

Complications of the MCL due to the disease process itself based on the site of MCL involvement include splenic rupture due to splenomegaly, GI bleeding or obstruction or perforation due to MCL in the gastrointestinal tract, and tumor lysis in the blastoid variant of MCL are all the considerations.[34] Due to chemotherapy and stem cell transplants, complications of life-threatening infections, neutropenic sepsis, cytopenias needing transfusions, nausea, vomiting, and hair loss are possible. With targeted drug approvals in MCL with agents like ibrutinib, aBTK inhibitor, hypertension, arrhythmias, diarrhea, skin rashes, and bleeding risk are reported. These side effects are felt to be more related to off-target actions on EGFR, ITK, and PI3K. Second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more specific to BTK and have fewer off-target side effects in terms of hypertension, arrhythmias, or rashes.[14] BCL-2 inhibitor venetoclax is now approved for MCL venetoclax drug tumor lysis syndrome, while lenalidomide edema, cytopenias, risk of blood clots, and diarrhea are expected complications and or side effects to be aware of. Brexucabtagene (CAR-T cell therapy ) is associated with encephalopathy, cytopenias, and pyrexia from cytokine release syndrome, which must be addressed during the treatments. ITK - Interleukin-2-inducible T-cell kinase, EGFR-epidermal growth factor inhibitor, PI3K-phosphoinositide 3-kinase.

Mantle cell lymphoma is a rare and conventionally aggressive B-cell lymphoma with a heterogeneous disease profile. Cases are typically diagnosed with diffuse cyclin D1 positivity by immunohistochemistry or FISH for t(11;14). Rare cases that are negative for cyclin D1 for t(11;14) are positive for SOX11 by immunohistochemistry. High Ki67 proliferation index and p53 mutations are adverse prognostic findings and likely imply the need for more prompt treatment and clinical trial enrollment if no good response. Chemoimmunotherapy is conventionally the choice as front-line therapy among patients necessitating treatment with a potential role of targeted therapies in the salvage setting. The role of autologous and allogeneic bone marrow transplant and stratifying patients as transplant eligible and ineligible in choosing the treatment choices are elucidated. The role of second-generation drugs in improving outcomes and the side effects of these drugs are discussed. Investigational new drugs alone and in combination are described.  Risk-adapted approaches in the pipeline for improving the care of mantle cell lymphoma patients are discussed.

Mantle cell lymphoma is typically an uncomplicated diagnosis, but morphologic variants may mimic other lymphoid neoplasms. Having a low threshold for ordering additional testing for cyclin D 1, SOX 11 immunohistochemistry, or confirmatory FISH studies will prevent misdiagnosis. The disorder is best managed by an interprofessional team that includes a hematologist-medical oncologist, internist, radiologist, radiation-oncologist, bone marrow transplant team, experienced nursing staff, and clinical trial teams. It is important to recognize the indolent form of MCL that might require monitoring with aggressive forms that require immediate systemic treatments. With the availability now of multiple second-line treatments in relapsed settings, including CAR-T cell treatments recognizing the complications and side effects related to these treatments can help guide the management of MCL patients effectively.